On April 17, 2026, Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab and appointed Ernst & Young LLP as its new independent registered public accounting firm, effective immediately. The prior firm had no adverse opinions on its financial statements for 2024 and 2025, but noted concerns about the company's continuation as a going concern.